Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC-18 in mild/moderate COVID-19 pneumonia
NCT04569227Phase 2Not yet recruiting
- Sponsor
- Enzychem Lifesciences
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mosedipimod in COVID-19 pneumonia, sponsored by Enzychem Lifesciences. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
mosedipimod
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04569227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569227.